Cargando…

A preclinical radiotherapy dosimetry audit using a realistic 3D printed murine phantom

Preclinical radiation research lacks standardized dosimetry procedures that provide traceability to a primary standard. Consequently, ensuring accuracy and reproducibility between studies is challenging. Using 3D printed murine phantoms we undertook a dosimetry audit of Xstrahl Small Animal Radiatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Biglin, Emma R., Aitkenhead, Adam H., Price, Gareth J., Chadwick, Amy L., Santina, Elham, Williams, Kaye J., Kirkby, Karen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042835/
https://www.ncbi.nlm.nih.gov/pubmed/35474242
http://dx.doi.org/10.1038/s41598-022-10895-5
Descripción
Sumario:Preclinical radiation research lacks standardized dosimetry procedures that provide traceability to a primary standard. Consequently, ensuring accuracy and reproducibility between studies is challenging. Using 3D printed murine phantoms we undertook a dosimetry audit of Xstrahl Small Animal Radiation Research Platforms (SARRPs) installed at 7 UK centres. The geometrically realistic phantom accommodated alanine pellets and Gafchromic EBT3 film for simultaneous measurement of the dose delivered and the dose distribution within a 2D plane, respectively. Two irradiation scenarios were developed: (1) a 10 × 10 mm(2) static field targeting the pelvis, and (2) a 5 × 5 mm(2) 90° arc targeting the brain. For static fields, the absolute difference between the planned dose and alanine measurement across all centres was 4.1 ± 4.3% (mean ± standard deviation), with an overall range of − 2.3 to 10.5%. For arc fields, the difference was − 1.2% ± 6.1%, with a range of − 13.1 to 7.7%. EBT3 dose measurements were greater than alanine by 2.0 ± 2.5% and 3.5 ± 6.0% (mean ± standard deviation) for the static and arc fields, respectively. 2D dose distributions showed discrepancies to the planned dose at the field edges. The audit demonstrates that further work on preclinical radiotherapy quality assurance processes is merited.